



Fourth Quarter and Full Year 2025 Earnings

EARNINGS PRESENTATION

February 4, 2026



Forward Looking Statements and Non-GAAP Financial Measures

FORWARD-LOOKING STATEMENTS

Statements in this presentation that are not strictly historical, including statements regarding anticipated financial results, global and regional economic conditions, industry trends, geopolitical events, future acquisitions, impact of trade and spending policies, the ability to execute the planned strategies, interest rate and current exchange rate impact, future prospects, shareholder value, and any other statements identified by their use of words like "anticipate," "expect," "believe," "outlook," "guidance," "target", or "will" or other words of similar meaning, are "forward-looking statements" within the meaning of the United States federal securities laws. Factors that could cause actual results to differ materially from those in the forward-looking statements include, among other things: deterioration of or instability in the economy, the markets we serve, international trade policies and deteriorating trade relations with other countries, including imposition of tariffs and retaliatory tariffs between United States and China and other countries, responsive economic nationalism, trade restrictions, and enhanced regulation, impact of any prolonged government shutdown, the financial markets, geopolitical conditions and conflicts, security breaches, data exfiltration, or other disruptions of our information technology systems, supply chain constraints, our ability to adjust purchases and manufacturing capacity to reflect market conditions, reliance on sole sources of supply, contractions or lower growth rates and cyclical of markets we serve, competition, changes in industry standards and governmental regulations, our ability to manage leadership transitions and recruit and retain key employees, our ability to successfully identify, consummate, integrate and realize the anticipated value of appropriate acquisitions or otherwise effectively deploy our capital, our ability to develop and successfully market new products, software, and services and expand into new markets, the potential for improper conduct by our employees, agents or business partners, contingent liabilities relating to acquisitions and divestitures, impact of changes to tax laws, our compliance with applicable laws and regulations and changes in applicable laws and regulations, risks relating to international economic, geopolitical, including war and sanctions, legal, compliance and business factors, risks relating to potential impairment of goodwill and other intangible assets, currency exchange rates, tax audits and changes in our tax rate and income tax liabilities, the impact of our debt obligations on our operations, litigation and other contingent liabilities including intellectual property and environmental, health and safety matters, our ability to adequately protect our intellectual property rights, risks relating to product, service or software defects, product liability and recalls, risks relating to product manufacturing, our relationships with and the performance of our channel partners, commodity costs and surcharges, adverse effects of restructuring activities, our separation into two independent, publicly-traded companies, risk related to tax treatment of our prior separations, impact of our indemnification obligation to Ralliant and Vontier, impact of changes to U.S. GAAP, labor matters, and disruptions relating to man-made and natural disasters and climate change. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in our SEC filings, including our Annual Report on Form 10-K for the year ended December 31, 2024 and Quarterly Reports on Form 10-Q for the subsequent quarters. These forward-looking statements speak only as of the date of this presentation, and Fortive does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise.

NON-GAAP FINANCIAL MEASURES

This presentation contains references to financial measures not presented in accordance with generally accepted accounting principles ("GAAP"). We have not reconciled forward-looking targets or outlook regarding non-GAAP measures because any corresponding GAAP measures and the reconciliations thereto would require us to make estimates or assumptions with precision about acquisitions, currency transactions, capital and other expenditures and similar adjustments during the relevant period. Information required by Regulation G with respect to historical non-GAAP financial measures are set forth in the appendix to this presentation and the "Investors" section of our website, www.fortive.com, under the heading "Financial Results".

PRECISION TECHNOLOGIES SEPARATION

On June 28, 2025, the Company completed the separation (the "Separation") of its former Precision Technologies segment by distributing to Fortive shareholders on a pro rata basis all of the issued and outstanding common stock of Ralliant Corporation ("Ralliant"), the entity incorporated to hold the PT businesses. The accounting requirements for reporting Ralliant as a discontinued operation were met when the Separation was completed. Accordingly, the accompanying financial information for all periods presented reflect this business as a discontinued operation. Unless otherwise indicated, all references in this report refer to continuing operations.

All growth or period changes refer to year-over-year comparisons unless otherwise stated. Forward looking financial information not otherwise presented as a range reflect assumptions underlying the midpoint of our forward-looking targets.

Key Messages



- 1 Solid execution at new Fortive continues with Q4 performance ahead of expectations
- 2 FY 2025 Adj. EPS of \$2.71 exceeded high end of guidance range (\$2.63 - \$2.67)
- 3 ~\$1.3B of share repurchases in second half of 2025 demonstrates continued commitment to disciplined capital allocation approach
- 4 Fortive *Accelerated* strategy in execution mode, driving continued confidence in medium-term financial framework and value creation opportunity
- 5 Initiating FY 2026 Adj. EPS guidance of \$2.90 to \$3.00

Fortive *Accelerated* Strategy

1

Faster Profitable Organic Growth

- Innovation Acceleration
- Commercial Acceleration
- Recurring Customer Value

Powered by FBS Amplified

Promising early indicators: accelerating new product introduction velocity, refocused commercial strategies driving regional acceleration, recurring revenue growth outpacing consolidated growth

2

Disciplined Capital Allocation

- Invest in organic growth
- Smaller bolt-on M&A
- Share repurchases
- Modest growing dividend

Deployed ~\$1.3B in 2H'25 to share repurchases, representing ~26M shares or ~8% of diluted shares outstanding

Revamped bolt-on M&A engine

3

Build and Maintain Investor Trust

- Clear expectations and consistent delivery
- Simplified guidance and disclosure
- Do what we say we will do

Exceeded expectations in Q3 and Q4 across key metrics

FY 2025 Adjusted EPS surpassed high end of guidance range



Demonstrated progress in Q3 & Q4

Ambition: 3-5 Year Total Shareholder Return > the S&P 500 Index¹

Fortive Results

Q4 2025 and FY 2025

	Q4 2025	FY 2025
Revenue	\$1,123M	\$4,159M
<i>Reported Growth</i>	+4.6%	+1.9%
<i>Core Growth</i>	+3.3%	+1.7%
Adj. Gross Profit	\$712M	\$2,652M
<i>Adj. Gross Margin</i>	63.4%	63.8%
<i>Adj. Gross Profit Growth (YoY)</i>	+2.3%	+1.2%
Adj. EBITDA	\$358M	\$1,233M
<i>Adj. EBITDA Margin</i>	31.9%	29.6%
<i>Adj. EBITDA Growth (YoY)</i>	+7.8%	+6.1%
Adj. EPS	\$0.90	\$2.71
<i>Adj. EPS Growth (YoY)</i>	+12.5%	+12.4%
Free Cash Flow	\$314M	\$931M
<i>FCF Conversion on Adj. Net Income</i>	109%	103%

Q4 COMMENTARY

- Core growth of +3% reflects growth at both segments and growth across all major regions
- Adjusted Gross Profit up modestly year-over-year; Adj. Gross Margin impacted by product mix, net effect of tariffs and related countermeasures, and targeted growth investments
- Adj. EBITDA grew +8% year-over-year and margin expanded to ~32%, reflecting operating leverage, disciplined cost control and continued corporate cost optimization
- Adj. EPS grew ~13% year-over-year, driven by Adj. EBITDA growth and favorable impact of share repurchases
- FY 2025 Free Cash Flow Conversion on Adj. Net Income >100%

Intelligent Operating Solutions

Q4 2025 and FY 2025

	Q4 2025	FY 2025
Revenue	\$770M	\$2,856M
<i>Reported Growth</i>	+5.3%	+2.3%
<i>Core Growth</i>	+4.1%	+2.1%
Adj. Gross Profit	\$514M	\$1,895M
<i>Adj. Gross Margin</i>	66.7%	66.3%
<i>Adj. Gross Profit Growth (YoY)</i>	+3.3%	+1.3%
Adj. EBITDA	\$288M	\$1,002M
<i>Adj. EBITDA Margin</i>	37.4%	35.1%
<i>Adj. EBITDA Growth (YoY)</i>	+7.6%	+5.6%

Q4 COMMENTARY

- Core revenue growth of +4% with solid performance in professional instrumentation, Facilities and Asset Lifecycle software, and gas detection
- Adj. Gross Profit grew +3%; Adj. Gross Margin of ~67%, with year-over-year performance impacted by product mix and the net impact of tariffs and related countermeasures
- Adj. EBITDA grew +8%, driven by operating leverage and disciplined cost management, net of growth investments

Advanced Healthcare Solutions

Q4 2025 and FY 2025

	Q4 2025	FY 2025
Revenue	\$353M	\$1,303M
<i>Reported Growth</i>	+3.2%	+1.2%
<i>Core Growth</i>	+1.6%	+0.8%
Adj. Gross Profit	\$198M	\$758M
<i>Adj. Gross Margin</i>	56.2%	58.2%
<i>Adj. Gross Profit Growth (YoY)</i>	(0.3)%	+1.2%
Adj. EBITDA	\$92M	\$341M
<i>Adj. EBITDA Margin</i>	26.0%	26.2%
<i>Adj. EBITDA Growth (YoY)</i>	(2.6)%	+0.3%

Q4 COMMENTARY

- Core revenue growth of +1.6% driven by continued strength in healthcare software; demand trends for healthcare equipment & consumables improved again in Q4, though macro headwinds remain
- Adj. Gross Profit was ~flat; Adj. Gross Margins of ~56%, reflecting targeted growth investments
- Adj. EBITDA of \$92M; year-over-year performance reflects accelerated innovation and commercial investments to support strategic growth initiatives

Balance Sheet & Capital Allocation

Q4 2025 and FY 2025

Balance Sheet

	As of December 31, 2025
Cash and equivalents	\$0.4B
Gross debt	\$3.2B
Net debt	\$2.8B

Leverage

FY 2025 Adj. EBITDA	\$1.2B
Gross Debt / Adj. EBITDA	~2.6X
Net Debt / Adj. EBITDA	~2.3X

Cash Flow

	FY 2025
Operating Cash Flow	\$1,036M
Capital Expenditures	\$105M
Free Cash Flow	\$931M
Free Cash Conversion on Adj. Net Income	103%

COMMENTARY

- Deployed ~\$265M towards share repurchase in Q4, representing ~5M shares at an average price of \$51.80
- In second half of 2025, deployed ~\$1.3B to share repurchases, representing ~26M shares or ~8% of diluted shares outstanding
- Ample capacity and flexibility to execute our capital deployment priorities, always with a disciplined focus on allocating capital to optimize shareholder returns over the medium to long term

FY 2026 Guidance

Adj. EPS | FY 2026

\$2.90 to \$3.00



Fortive *Accelerated*

Innovating essential
technologies to keep our
world **safe** and **productive**





Appendix & Supplemental Reconciliation Data

1H / 2H 2025 Results

	Fortive		IOS		AHS	
	1H 2025	2H 2025	1H 2025	2H 2025	1H 2025	2H 2025
Revenue	\$2,009.5M	\$2,149.6M	\$1,387.8M	\$1,468.5M	\$621.7M	\$681.1M
Reported Growth	+0.3%	+3.5%	+0.5%	+4.0%	(0.3)%	+2.5%
Core Growth	+0.7%	+2.6%	+0.9%	+3.2%	+0.2%	+1.3%
Adj. Gross Profit	\$1,289.7M	\$1,362.4M	\$922.1M	\$972.4M	\$367.6M	\$390.0M
Adj. Gross Margin	64.2%	63.4%	66.4%	66.2%	59.1%	57.3%
Adj. Gross Profit Growth (YoY)	+0.6%	+1.9%	+0.2%	+2.3%	+1.5%	+0.9%
Adj. EBITDA	\$565.5M	\$667.3M	\$471.9M	\$530.0M	\$157.3M	\$184.0M
Adj. EBITDA Margin	28.1%	31.0%	34.0%	36.1%	25.3%	27.0%
Adj. EBITDA Growth (YoY)	+2.9%	+9.0%	+3.9%	+7.2%	(1.4)%	+1.8%
Adj. EPS	\$1.13	\$1.58				
Adj. EPS Growth (YoY)	+10.8%	+13.7%				

CORE REVENUE GROWTH

Components of Revenue Growth

	Three Months Ended					
	December 31, 2025			December 31, 2024		
	Intelligent Operating Solutions	Advanced Healthcare Solutions	Total Fortive	Intelligent Operating Solutions	Advanced Healthcare Solutions	Total Fortive
Total revenue growth (GAAP)	5.3 %	3.2 %	4.6 %	4.3 %	3.2 %	3.9 %
Excluding impact of:						
Acquisitions and divestitures	0.4 %	— %	0.2 %	(0.2)%	— %	(0.2)%
Currency exchange rates	(1.6)%	(1.6)%	(1.5)%	0.3 %	1.5 %	0.8 %
Core revenue growth (Non-GAAP)	4.1 %	1.6 %	3.3 %	4.4 %	4.7 %	4.5 %
Components of Revenue Growth						
Year Ended						
	December 31, 2025			December 31, 2024		
	Intelligent Operating Solutions	Advanced Healthcare Solutions	Total Fortive	Intelligent Operating Solutions	Advanced Healthcare Solutions	Total Fortive
	2.3 %	1.2 %	1.9 %	4.1 %	4.7 %	4.3 %
Total revenue growth (GAAP)	2.3 %	1.2 %	1.9 %	4.1 %	4.7 %	4.3 %
Excluding impact of:						
Acquisitions and divestitures	0.4 %	— %	0.2 %	(0.8)%	— %	(0.6)%
Currency exchange rates	(0.6)%	(0.4)%	(0.4)%	0.2 %	1.4 %	0.6 %
Core revenue growth (Non-GAAP)	2.1 %	0.8 %	1.7 %	3.5 %	6.1 %	4.3 %
Components of Revenue Growth						
	1H 2025			2H 2025		
	Intelligent Operating Solutions	Advanced Healthcare Solutions	Total Fortive	Intelligent Operating Solutions	Advanced Healthcare Solutions	Total Fortive
	0.5 %	(0.3)%	0.3 %	4.0 %	2.5 %	3.5 %
Total revenue growth (GAAP)	0.5 %	(0.3)%	0.3 %	4.0 %	2.5 %	3.5 %
Excluding impact of:						
Acquisitions and divestitures	0.3 %	— %	0.2 %	0.4 %	— %	0.3 %
Currency exchange rates	0.1 %	0.5 %	0.2 %	(1.2)%	(1.2)%	(1.2)%
Core revenue growth (Non-GAAP)	0.9 %	0.2 %	0.7 %	3.2 %	1.3 %	2.6 %

ADJUSTED GROSS PROFIT AND ADJUSTED GROSS PROFIT MARGIN

\$ in millions	Three Months Ended December 31, 2025			Three Months Ended December 31, 2024		
	Intelligent Operating Solutions	Advanced Healthcare Solutions	Total Fortive	Intelligent Operating Solutions	Advanced Healthcare Solutions	Total Fortive
Revenue (GAAP)	\$ 769.7	\$ 352.8	\$ 1,122.5	\$ 730.9	\$ 341.9	\$ 1,072.8
Gross Profit (GAAP)	\$ 510.8	\$ 198.1	\$ 708.9	\$ 496.6	\$ 198.9	\$ 695.5
Discrete Restructuring Charges	2.7	0.2	2.9	0.6	—	0.6
Adjusted Gross Profit (Non-GAAP)	\$ 513.5	\$ 198.3	\$ 711.8	\$ 497.2	\$ 198.9	\$ 696.1
Gross Profit Margin (GAAP)	66.4 %	56.2 %	63.2 %	67.9 %	58.2 %	64.8 %
Adjusted Gross Profit Margin (Non-GAAP)	66.7 %	56.2 %	63.4 %	68.0 %	58.2 %	64.9 %
\$ in millions	Year Ended December 31, 2025			Year Ended December 31, 2024		
	Intelligent Operating Solutions	Advanced Healthcare Solutions	Total Fortive	Intelligent Operating Solutions	Advanced Healthcare Solutions	Total Fortive
Revenue (GAAP)	\$ 2,856.3	\$ 1,302.8	\$ 4,159.1	\$ 2,793.2	\$ 1,287.7	\$ 4,080.9
Gross Profit (GAAP)	\$ 1,883.7	\$ 757.4	\$ 2,641.1	\$ 1,870.3	\$ 748.8	\$ 2,619.1
Discrete Restructuring Charges	10.8	0.2	11.0	0.6	—	0.6
Adjusted Gross Profit (Non-GAAP)	\$ 1,894.5	\$ 757.6	\$ 2,652.1	\$ 1,870.9	\$ 748.8	\$ 2,619.7
Gross Profit Margin (GAAP)	65.9 %	58.1 %	63.5 %	67.0 %	58.2 %	64.2 %
Adjusted Gross Profit Margin (Non-GAAP)	66.3 %	58.2 %	63.8 %	67.0 %	58.2 %	64.2 %

ADJUSTED GROSS PROFIT AND ADJUSTED GROSS PROFIT MARGIN - FIRST HALF AND SECOND HALF OF YEAR

\$ in millions	1H 2025			1H 2024		
	Intelligent Operating Solutions	Advanced Healthcare Solutions	Total Fortive	Intelligent Operating Solutions	Advanced Healthcare Solutions	Total Fortive
Revenue (GAAP)	\$ 1,387.8	\$ 621.7	\$ 2,009.5	\$ 1,381.0	\$ 623.4	\$ 2,004.4
Gross Profit (GAAP)	\$ 915.4	\$ 367.6	\$ 1,283.0	\$ 920.0	\$ 362.1	\$ 1,282.1
Discrete Restructuring Charges	6.7	—	6.7	—	—	—
Adjusted Gross Profit (Non-GAAP)	\$ 922.1	\$ 367.6	\$ 1,289.7	\$ 920.0	\$ 362.1	\$ 1,282.1
Gross Profit Margin (GAAP)	66.0 %	59.1 %	63.8 %	66.6 %	58.1 %	64.0 %
Adjusted Gross Profit Margin (Non-GAAP)	66.4 %	59.1 %	64.2 %	66.6 %	58.1 %	64.0 %
\$ in millions	2H 2025			2H 2024		
	Intelligent Operating Solutions	Advanced Healthcare Solutions	Total Fortive	Intelligent Operating Solutions	Advanced Healthcare Solutions	Total Fortive
Revenue (GAAP)	\$ 1,468.5	\$ 681.1	\$ 2,149.6	\$ 1,412.2	\$ 664.3	\$ 2,076.5
Gross Profit (GAAP)	\$ 968.3	\$ 389.8	\$ 1,358.1	\$ 950.3	\$ 386.7	\$ 1,337.0
Discrete Restructuring Charges	4.1	0.2	4.3	0.6	—	0.6
Adjusted Gross Profit (Non-GAAP)	\$ 972.4	\$ 390.0	\$ 1,362.4	\$ 950.9	\$ 386.7	\$ 1,337.6
Gross Profit Margin (GAAP)	65.9 %	57.2 %	63.2 %	67.3 %	58.2 %	64.4 %
Adjusted Gross Profit Margin (Non-GAAP)	66.2 %	57.3 %	63.4 %	67.3 %	58.2 %	64.4 %

ADJUSTED EBITDA AND ADJUSTED EBITDA MARGIN FROM CONTINUING OPERATIONS

\$ in millions	Three Months Ended		Year Ended	
	December 31, 2025	December 31, 2024	December 31, 2025	December 31, 2024
Revenue (GAAP)	\$ 1,122.5	\$ 1,072.8	\$ 4,159.1	\$ 4,080.9
Net Earnings from Continuing Operations (GAAP)	\$ 191.5	\$ 193.2	\$ 532.7	\$ 482.5
Interest expense, net	31.0	33.0	120.5	152.8
Income taxes	2.4	(13.0)	69.5	23.8
Depreciation	18.1	15.9	70.1	61.6
Amortization	93.2	92.2	367.5	369.3
EBITDA from Continuing Operations (Non-GAAP)	336.2	321.3	1,160.3	1,090.0
Pretax acquisition, divestiture, and Separation related items ^(a)	2.1	0.2	42.0	1.9
Pretax discrete restructuring charges	18.5	10.6	32.0	10.6
Pretax foreign currency transaction (gains) and losses related to Euro-denominated debt	1.2	—	0.7	—
Pretax gain from divestiture	(0.1)	—	(2.2)	—
Pretax losses from equity investments	—	—	—	39.4
Pretax charitable contribution expense	—	—	—	20.0
Adjusted Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) from Continuing Operations (Non-GAAP)	\$ 357.9	\$ 332.1	\$ 1,232.8	\$ 1,161.9
Net Earnings Margin from Continuing Operations (GAAP)	17.1 %		18.0 %	
Adjusted EBITDA Margin from Continuing Operations (Non-GAAP)	31.9 %		31.0 %	

(a) Includes pretax transaction costs, acquisition related fair value adjustments to inventory, integration costs, corresponding restructuring charges related to acquisitions, and certain Separation-related costs recorded in Earnings from continuing operations.

The sum of the components of adjusted EBITDA may not equal due to rounding.

ADJUSTED EBITDA AND ADJUSTED EBITDA MARGIN FROM CONTINUING OPERATIONS - FIRST HALF AND SECOND HALF OF YEAR

\$ in millions	1H		2H			
	2025	2024	2025	2024		
Revenue (GAAP)	\$ 2,009.5	\$ 2,004.4	\$ 2,149.6	\$ 2,076.5		
Net Earnings from Continuing Operations (GAAP)	\$ 224.2	\$ 177.8	\$ 308.5	\$ 304.7		
Interest expense, net	64.1	82.7	56.4	70.1		
Income taxes	49.1	39.2	20.4	(15.4)		
Depreciation	34.4	29.9	35.7	31.7		
Amortization	182.8	185.1	184.7	184.2		
EBITDA from Continuing Operations (Non-GAAP)	554.6	514.7	605.7	575.3		
Pretax acquisition, divestiture, and Separation related items ^(a)	1.6	1.6	40.4	0.3		
Pretax discrete restructuring charges	11.4	—	20.6	10.6		
Pretax foreign currency transaction (gains) and losses related to Euro-denominated debt	—	—	0.7	—		
Pretax gain from divestiture	(2.1)	—	(0.1)	—		
Pretax losses from equity investments	—	13.2	—	26.2		
Pretax charitable contribution expense	—	20.0	—	—		
Adjusted EBITDA from Continuing Operations (Non-GAAP)	\$ 565.5	\$ 549.5	\$ 667.3	\$ 612.4		
Net Earnings Margin from Continuing Operations (GAAP)	11.2 %		8.9 %		14.4 %	14.7 %
Adjusted EBITDA Margin from Continuing Operations (Non-GAAP)	28.1 %		27.4 %		31.0 %	29.5 %

(a) Includes pretax transaction costs, acquisition related fair value adjustments to inventory, integration costs, corresponding restructuring charges related to acquisitions, and certain Separation-related costs recorded in Earnings from continuing operations.

The sum of the components of adjusted EBITDA may not equal due to rounding.

FORTIVE CONTINUING OPERATIONS: OPERATING PROFIT & OPERATING PROFIT MARGIN TO ADJUSTED EBITDA AND ADJUSTED MARGIN BRIDGE

\$ in millions	Three Months Ended				Year Ended	
	December 31, 2025		December 31, 2024		December 31, 2025	December 31, 2024
Revenue (GAAP)	\$ 1,122.5	\$ 1,072.8	\$ 4,159.1	\$ 4,080.9		
Operating Profit (GAAP)	\$ 225.5	\$ 212.2	\$ 720.2	\$ 716.3		
Amortization of acquisition-related intangible assets and non-cash impairments	93.2	92.2	367.5	369.3		
Acquisition, divestiture, and Separation related items ^(a)	2.1	0.2	42.0	1.9		
Discrete restructuring charges	18.5	10.6	32.0	10.6		
Adjusted Operating Profit (Non-GAAP)	\$ 339.3	\$ 315.2	\$ 1,161.7	\$ 1,098.1		
Depreciation	18.1	15.9	70.1	61.6		
Other	0.5	1.0	1.0	2.2		
Adjusted EBITDA from Continuing Operations (Non-GAAP)	\$ 357.9	\$ 332.1	\$ 1,232.8	\$ 1,161.9		
Operating Profit Margin (GAAP)	20.1 %	19.8 %	17.3 %	17.6 %		
Adjusted Operating Profit Margin (Non-GAAP)	30.2 %	29.4 %	27.9 %	26.9 %		
Adjusted EBITDA Margin from Continuing Operations (Non-GAAP)	31.9 %	31.0 %	29.6 %	28.5 %		

^(a) Includes pretax transaction costs, acquisition related fair value adjustments to inventory, integration costs and corresponding restructuring charges related to acquisitions, and certain Separation-related costs recorded in Earnings from continuing operations.

The sum of the components of adjusted operating profit may not equal due to rounding.

SEGMENT ADJUSTED EBITDA AND SEGMENT ADJUSTED EBITDA MARGIN

\$ in millions	Three Months Ended December 31, 2025				Three Months Ended December 31, 2024			
	Intelligent Operating Solutions	Advanced Healthcare Solutions	Corporate	Total Fortive	Intelligent Operating Solutions	Advanced Healthcare Solutions	Corporate	Total Fortive
Revenue (GAAP)	\$ 769.7	\$ 352.8	\$ —	\$ 1,122.5	\$ 730.9	\$ 341.9	\$ —	\$ 1,072.8
Operating Profit (GAAP)	\$ 212.2	\$ 38.6	\$ (25.3)	\$ 225.5	\$ 200.8	\$ 42.7	\$ (31.3)	\$ 212.2
Amortization of acquisition-related intangible assets	47.5	45.7	—	93.2	46.6	45.6	—	92.2
Acquisition, divestiture, and Separation related items ^(a)	0.4	0.1	1.6	2.1	0.2	—	—	0.2
Discrete restructuring charges	15.0	2.5	1.0	18.5	10.0	0.6	—	10.6
Adjusted Operating Profit (Non-GAAP)	\$ 275.1	\$ 86.9	\$ (22.7)	\$ 339.3	\$ 257.6	\$ 88.9	\$ (31.3)	\$ 315.2
Depreciation	13.0	4.8	—	—	\$ 10.2	\$ 5.2	—	—
Adjusted EBITDA (Non-GAAP)	\$ 288.1	\$ 91.7	—	—	\$ 267.8	\$ 94.1	—	—
Operating Profit Margin (GAAP)	27.6 %	10.9 %	—	20.1 %	27.5 %	12.5 %	—	19.8 %
Adjusted Operating Profit Margin (Non-GAAP)	35.7 %	24.6 %	—	30.2 %	35.2 %	26.0 %	—	29.4 %
Adjusted EBITDA Margin (Non-GAAP)	37.4 %	26.0 %	—	—	36.6 %	27.5 %	—	—

(a) Includes pretax transaction costs, acquisition related fair value adjustments to inventory, integration costs, corresponding restructuring charges related to acquisitions, and certain Separation-related costs recorded in Earnings from continuing operations.

The sum of the components of adjusted operating profit may not equal due to rounding.

SEGMENT ADJUSTED EBITDA AND SEGMENT ADJUSTED EBITDA MARGIN

\$ in millions	Year Ended December 31, 2025				Year Ended December 31, 2024			
	Intelligent Operating Solutions	Advanced Healthcare Solutions	Corporate	Total Fortive	Intelligent Operating Solutions	Advanced Healthcare Solutions	Corporate	Total Fortive
Revenue (GAAP)	\$ 2,856.3	\$ 1,302.8	\$ —	\$ 4,159.1	\$ 2,793.2	\$ 1,287.7	\$ —	\$ 4,080.9
Operating Profit (GAAP)	\$ 738.3	\$ 138.6	\$ (156.7)	\$ 720.2	\$ 708.0	\$ 138.5	\$ (130.2)	\$ 716.3
Amortization of acquisition-related intangible assets	187.1	180.4	—	367.5	188.3	181.0	—	369.3
Acquisition, divestiture, and Separation related items ^(a)	0.9	0.2	40.9	42.0	1.9	—	—	1.9
Discrete restructuring charges	26.3	2.6	3.1	32.0	10.0	0.6	—	10.6
Adjusted Operating Profit (Non-GAAP)	\$ 952.6	\$ 321.8	\$ (112.7)	\$ 1,161.7	\$ 908.2	\$ 320.1	\$ (130.2)	\$ 1,098.1
Depreciation	49.3	19.5	—	—	\$ 40.5	\$ 20.2	—	—
Adjusted EBITDA (Non-GAAP)	\$ 1,001.9	\$ 341.3	—	—	\$ 948.7	\$ 340.3	—	—
Operating Profit Margin (GAAP)	25.8 %	10.6 %	—	17.3 %	25.3 %	10.8 %	—	17.6 %
Adjusted Operating Profit Margin (Non-GAAP)	33.4 %	24.7 %	—	27.9 %	32.5 %	24.9 %	—	26.9 %
Adjusted EBITDA Margin (Non-GAAP)	35.1 %	26.2 %	—	—	34.0 %	26.4 %	—	—

(a) Includes pretax transaction costs, acquisition related fair value adjustments to inventory, integration costs, corresponding restructuring charges related to acquisitions, and certain Separation-related costs recorded in Earnings from continuing operations.

The sum of the components of adjusted operating profit may not equal due to rounding.

SEGMENT ADJUSTED EBITDA AND SEGMENT ADJUSTED EBITDA MARGIN - FIRST HALF AND SECOND HALF OF YEAR

\$ in millions	1H 25				1H 24			
	Intelligent Operating Solutions	Advanced Healthcare Solutions	Corporate	Total Fortive	Intelligent Operating Solutions	Advanced Healthcare Solutions	Corporate	Total Fortive
Revenue (GAAP)	\$ 1,387.8	\$ 621.7	\$ —	\$ 2,009.5	\$ 1,381.0	\$ 623.4	\$ —	\$ 2,004.4
Operating Profit (GAAP)	\$ 345.4	\$ 57.5	\$ (67.8)	\$ 335.1	\$ 338.2	\$ 59.1	\$ (65.2)	\$ 332.1
Amortization of acquisition-related intangible assets	93.2	89.6	—	182.8	94.8	90.3	—	185.1
Acquisition, divestiture, and Separation related items ^(a)	0.4	—	1.2	1.6	1.6	—	—	1.6
Discrete restructuring charges	9.3	—	2.1	11.4	—	—	—	—
Adjusted Operating Profit (Non-GAAP)	\$ 448.3	\$ 147.1	\$ (64.5)	\$ 530.9	\$ 434.6	\$ 149.4	\$ (65.2)	\$ 518.8
Depreciation	23.6	10.2	—	—	\$ 19.6	\$ 10.2	—	—
Adjusted EBITDA (Non-GAAP)	\$ 471.9	\$ 157.3			\$ 454.2	\$ 159.6		
Operating Profit Margin (GAAP)	24.9 %	9.2 %			16.7 %	24.5 %	9.5 %	16.6 %
Adjusted Operating Profit Margin (Non-GAAP)	32.3 %	23.7 %			26.4 %	31.5 %	24.0 %	25.9 %
Adjusted EBITDA Margin (Non-GAAP)	34.0 %	25.3 %			32.9 %	25.6 %		

(a) Includes pretax transaction costs, acquisition related fair value adjustments to inventory, integration costs, corresponding restructuring charges related to acquisitions, and certain Separation-related costs recorded in Earnings from continuing operations.

The sum of the components of adjusted operating profit may not equal due to rounding.

\$ in millions	2H 25				2H 24			
	Intelligent Operating Solutions	Advanced Healthcare Solutions	Corporate	Total Fortive	Intelligent Operating Solutions	Advanced Healthcare Solutions	Corporate	Total Fortive
Revenue (GAAP)	\$ 1,468.5	\$ 681.1	\$ —	\$ 2,149.6	\$ 1,412.2	\$ 664.3	\$ —	\$ 2,076.5
Operating Profit (GAAP)	\$ 392.9	\$ 81.1	\$ (88.9)	\$ 385.1	\$ 369.8	\$ 79.4	\$ (65.0)	\$ 384.2
Amortization of acquisition-related intangible assets	93.9	90.8	—	184.7	93.5	90.7	—	184.2
Acquisition, divestiture, and separation related items ^(a)	0.5	0.2	39.7	40.4	0.3	—	—	0.3
Discrete restructuring charges	17.0	2.6	1.0	20.6	10.0	0.6	—	10.6
Adjusted Operating Profit (Non-GAAP)	\$ 504.3	\$ 174.7	\$ (48.2)	\$ 630.8	\$ 473.6	\$ 170.7	\$ (65.0)	\$ 579.3
Depreciation	25.7	9.3	—	—	\$ 20.9	\$ 10.0	—	—
Adjusted EBITDA (Non-GAAP)	\$ 530.0	\$ 184.0			\$ 494.5	\$ 180.7		
Operating Profit Margin (GAAP)	26.8 %	11.9 %			17.9 %	26.2 %	12.0 %	18.5 %
Adjusted Operating Profit Margin (Non-GAAP)	34.3 %	25.6 %			29.3 %	33.5 %	25.7 %	27.9 %
Adjusted EBITDA Margin (Non-GAAP)	36.1 %	27.0 %			35.0 %	27.2 %		

(a) Includes pretax transaction costs, acquisition related fair value adjustments to inventory, integration costs, corresponding restructuring charges related to acquisitions, and certain Separation-related costs recorded in Earnings from continuing operations.

The sum of the components of adjusted operating profit may not equal due to rounding.

ADJUSTED NET EARNINGS AND ADJUSTED DILUTED NET EPS FROM CONTINUING OPERATIONS

\$ in millions, except per share amounts	Three Months Ended						Year Ended					
	December 31, 2025			December 31, 2024			December 31, 2025			December 31, 2024		
		Per share value			Per share value		Per share value		Per share value		Per share value	
Net Earnings and Net Earnings Per Share from Continuing Operations (GAAP)	\$ 191.5	\$ 0.60	\$ 193.2	\$ 0.56	\$ 532.7	\$ 1.59	\$ 482.5	\$ 1.37				
Pretax amortization of acquisition related intangible assets	93.2	0.29	92.2	0.26	367.5	1.10	369.3	1.05				
Pretax acquisition, divestiture, and Separation related items ^(a)	2.1	0.01	0.2	—	42.0	0.13	1.9	0.01				
Pretax discrete restructuring charges	18.5	0.06	10.6	0.03	32.0	0.10	10.6	0.03				
Pretax foreign currency transaction (gains) and losses related to Euro-denominated debt	1.2	—	—	—	0.7	—	—	—				
Pretax gain from divestiture ^(b)	(0.1)	—	—	—	(2.2)	(0.01)	—	—				
Pretax losses from equity investments	—	—	—	—	—	—	39.4	0.11				
Pretax charitable contribution expense	—	—	—	—	—	—	20.0	0.06				
Tax effect of the adjustments reflected above ^(b)	(17.5)	(0.06)	(16.4)	(0.05)	(66.6)	(0.20)	(73.2)	(0.22)				
Adjusted Net Earnings and Adjusted Net Earnings Per Share from Continuing Operations (Non-GAAP)	\$ 288.9	\$ 0.90	\$ 279.8	\$ 0.80	\$ 906.1	\$ 2.71	\$ 850.5	\$ 2.41				
Average Common Diluted Stock Outstanding (shares in millions)		319.4		348.0		334.6		352.8				

(a) Includes pretax transaction costs, acquisition related fair value adjustments to inventory, integration costs, corresponding restructuring charges related to acquisitions, and certain Separation-related costs recorded in Earnings from continuing operations.

(b) The gain from divestiture in 2025 had no tax impact. The tax effect of the adjustments includes all other line items above.

The sum of the components of adjusted diluted net earnings per share may not equal due to rounding.

ADJUSTED NET EARNINGS AND ADJUSTED DILUTED NET EPS FROM CONTINUING OPERATIONS - FIRST HALF AND SECOND HALF OF YEAR

\$ in millions, except per share amounts	1H						2H					
	2025			2024			2025			2024		
		Per share value			Per share value			Per share value			Per share value	
Net Earnings and Net Earnings Per Share from Continuing Operations (GAAP)	\$ 224.2	\$ 0.65	\$ 177.8	\$ 0.50	\$ 308.5	\$ 0.95	\$ 304.7	\$ 0.87				
Pretax amortization of acquisition related intangible assets	182.8	0.53	185.1	0.52	184.7	0.57	184.2	0.53				
Pretax acquisition, divestiture, and Separation related items ^(a)	1.6	—	1.6	—	40.4	0.12	0.3	—				
Pretax discrete restructuring charges	11.4	0.03	—	—	20.6	0.06	10.6	0.03				
Pretax foreign currency transaction (gains) and losses related to Euro-denominated debt	—	—	—	—	0.7	—	—	—				
Pretax gain from divestiture ^(b)	(2.1)	(0.01)	—	—	(0.1)	—	—	—				
Pretax losses from equity investments	—	—	13.2	0.04	—	—	26.2	0.07				
Pretax charitable contribution expense	—	—	20.0	0.06	—	—	—	—				
Tax effect of the adjustments reflected above ^(b)	(29.0)	(0.07)	(34.4)	(0.10)	(37.6)	(0.12)	(38.8)	(0.11)				
Adjusted Net Earnings and Adjusted Net Earnings Per Share from Continuing Operations (Non-GAAP)	\$ 388.9	\$ 1.13	\$ 363.3	\$ 1.02	\$ 517.2	\$ 1.58	\$ 487.2	\$ 1.39				
Average Common Diluted Stock Outstanding (shares in millions)	343.2			355.4			326.4			350.2		

(a) Includes pretax transaction costs, acquisition related fair value adjustments to inventory, integration costs, corresponding restructuring charges related to acquisitions, and certain Separation-related costs recorded in Earnings from continuing operations.

(b) The gain from divestiture in 2025 had no tax impact. The tax effect of the adjustments includes all other line items above.

The sum of the components of adjusted diluted net earnings per share may not equal due to rounding.

FREE CASH FLOW FROM CONTINUING OPERATIONS (in millions)

	Three Months Ended				Year Ended December 31, 2025
	December 31, 2025	September 26, 2025	June 27, 2025	March 28, 2025	
Operating Cash Flows from Continuing Operations (GAAP)	\$ 344.2	\$ 294.7	\$ 205.0	\$ 191.8	\$ 1,035.7
Less: Purchases of property, plant & equipment (capital expenditures) (GAAP)	(30.4)	(28.6)	(25.0)	(21.1)	(105.1)
Free Cash Flow (Non-GAAP)	\$ 313.8	\$ 266.1	\$ 180.0	\$ 170.7	\$ 930.6
Adjusted Net Earnings from Continuing Operations (Non-GAAP)	\$ 288.9	\$ 228.3	\$ 197.8	\$ 191.1	\$ 906.1
Free Cash Flow Conversion on Adjusted Net Earnings from Continuing Operations	108.6 %	116.6 %	91.0 %	89.3 %	102.7 %
	Three Months Ended				Year Ended December 31, 2024
	December 31, 2024	September 27, 2024	June 28, 2024	March 29, 2024	
Operating Cash Flows from Continuing Operations (GAAP)	\$ 327.7	\$ 304.7	\$ 217.5	\$ 178.6	\$ 1,028.5
Less: Purchases of property, plant & equipment (capital expenditures) (GAAP)	(22.6)	(21.6)	(19.6)	(22.3)	(86.1)
Free Cash Flow (Non-GAAP)	\$ 305.1	\$ 283.1	\$ 197.9	\$ 156.3	\$ 942.4
Adjusted Net Earnings from Continuing Operations (Non-GAAP)	\$ 279.8	\$ 207.4	\$ 198.6	\$ 164.7	\$ 850.5
Free Cash Flow Conversion on Adjusted Net Earnings from Continuing Operations	109.0 %	136.5 %	99.6 %	94.9 %	110.8 %

